Mevacor meeting
This article was originally published in The Tan Sheet
Executive Summary
FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs advisory committees will convene Jan. 13-14 to consider J&J/Merck's NDA proposing an Rx-to-OTC switch of Mevacor (lovastatin 20 mg), the agency confirms Dec. 3. The meeting will begin at 8 am both days at the Holiday Inn, Bethesda, Md. J&J/Merck will present recently published data from its CUSTOM actual-use study in support of the switch (1"The Tan Sheet" Nov. 22, 2004, p. 8)...
You may also be interested in...
Mevacor OTC Study Shows Cholesterol-Lowering Consistent With Rx Statins
A cholesterol self-management program for OTC Mevacor was effective in deterring consumers from improperly purchasing the nonprescription version of the cholesterol-lowering drug, results from the CUSTOM actual-use study show
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.